To ask the Secretary of State for Health and Social Care, what steps have been taken to assess the effectiveness of (a) inhaled treatment for covid-19 and (b) trails carried out by Synairgen plc in Bradford Royal Infirmary and other hospitals.
22 October 2020
The Department with the National Institute for Health Research (NIHR) has established a single United Kingdom-wide process which labels COVID-19 research with the most potential with Urgent Public Health (UPH) status. Any trials evaluating the effectiveness of inhaled treatments are subject to this same process.
National and international trials are monitored by the RAPID-C19 initiative, which aims to get treatments for COVID-19 to National Health Service patients quickly and safely. This process begins with scanning all trials for COVID-19 treatments. Any promising drugs will be identified for further review.
Synairgen have been requested to submit a formal submission to UK-CTAP and NIHR UPH for review, where the inhaled interferon beta-1, SGN001 will be reviewed by a panel of independent experts to assess if it will be suitable to be incorporated into the RECOVERY+ trial or an independent trial, for Phase III.
UK-CTAP is an independent COVID-19 Therapeutics Advisory Panel, which will advise on what treatments should be proposed for testing through RECOVERY+. As with all other therapeutic compounds in trial, progress of the effectiveness will continue to be monitored by the Chief Medical Officer, NIHR UPH and RAPID C-19.